Assignee
KSQ THERAPEUTICS INC
US·18 granted patents·18 pending applications·36 citations·filing 2017–2025
Top patents by PatentIndex Score
36 records- 0196US11608500B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Granted Mar 21, 2023·5 cites·20 claims
- 0295US11459544B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Granted Oct 4, 2022·4 cites·20 claims
- 0395US11111493B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2020·Granted Sep 7, 2021·5 cites·21 claims
- 0494US11421228B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2021·Granted Aug 23, 2022·3 cites·16 claims
- 0594US11332713B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2020·Granted May 17, 2022·5 cites·45 claims
- 0694US11261428B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2019·Granted Mar 1, 2022·7 cites·24 claims
- 0793US12084682B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Granted Sep 10, 2024·1 cites·7 claims
- 0891US12123021B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Granted Oct 22, 2024·1 cites·12 claims
- 0988US12280111B2Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2024·Granted Apr 22, 2025·0 cites·20 claims
- 1086US11078483B1Methods for measuring and improving CRISPR reagent functionKSQ THERAPEUTICS INC·Filed 2017·Granted Aug 3, 2021·3 cites·22 claims
- 1185US11078481B1Methods for screening for cancer targetsKSQ THERAPEUTICS INC·Filed 2017·Granted Aug 3, 2021·2 cites·16 claims
- 1279US2023220380A1Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1376US2025195577A1Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1470US2019284553A1Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1569US11912987B2Methods for screening for cancer targetsKSQ THERAPEUTICS INC·Filed 2021·Granted Feb 27, 2024·0 cites·15 claims
- 1668US2023088186A1Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1765US11787813B2Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitorsKSQ THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·0 cites·30 claims
- 1865US2024034738A1Solid state forms of substituted pyrazolopyrimidines and uses thereofKSQ THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1964US11946163B2Methods for measuring and improving CRISPR reagent functionKSQ THERAPEUTICS INC·Filed 2021·Granted Apr 2, 2024·0 cites·7 claims
- 2064US11718624B2Solid state forms of substituted pyrazolopyrimidines and uses thereofKSQ THERAPEUTICS INC·Filed 2021·Granted Aug 8, 2023·0 cites·27 claims
- 2162US11485736B2Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitorsKSQ THERAPEUTICS INC·Filed 2019·Granted Nov 1, 2022·0 cites·45 claims
- 2261US12188045B2Guide RNA combinations and methods of useKSQ THERAPEUTICS INC·Filed 2022·Granted Jan 7, 2025·0 cites·18 claims
- 2359US2025213574A1Therapeutic combinations comprising ubiquitin- specific-processing protease 1 (usp1) inhibitors and chemotherapy agentsKSQ THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2457US2024182594A1Uses of antagonist, non-depleting ox40 antibodiesKSQ THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2557US2025161306A1Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumorsKSQ THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2657US2024228962A9Methods for expanding regulatory t cellsKSQ THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2757US2019284529A1Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2854US2025130220A1Lymphocyte potency assayKSQ THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2953US2023219965A1Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitorsKSQ THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3053US2023065636A1Compositions of substituted pyrazolopyrimidines and uses thereofKSQ THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3153US2024376428A1Methods for activation and expansion of tumor infiltrating lymphocytesKSQ THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3252US2022110974A1Gene-regulating compositions and methods for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3351US2023277533A1Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitorsKSQ THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3450US2023108584A1Methods for activation and expansion of tumor infiltrating lymphocytesKSQ THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3548US2020347386A1Combination gene targets for improved immunotherapyKSQ THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3644US12590312B2NR4A super-repressors and methods of use thereofKSQ THERAPEUTICS INC·Filed 2020·Granted Mar 31, 2026·0 cites·19 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →